62 related articles for article (PubMed ID: 11352498)
1. A novel and rapid prediction assay for the effectiveness of IL-6 receptor specific antisense oligonucleotides by proliferation inhibition of an interleukin-6 dependent cell line.
Lia Varga V; Falus A; Pallinger E; Novák I; Fülöp KA; Toth S; Rose-John S
Cell Biol Int; 2001; 25(3):253-6. PubMed ID: 11352498
[TBL] [Abstract][Full Text] [Related]
2. gp130-specific antisense oligonucleotides inhibit IL-6 signal inducing junB mRNA transcription in the human hepatoma cell line, HepG2.
Varga VL; Fülöp AK; Holub MC; Tóth S; Szalai C; Falus A
Cell Biol Int; 2001; 25(8):835-40. PubMed ID: 11482910
[TBL] [Abstract][Full Text] [Related]
3. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells.
Keller ET; Ershler WB
J Immunol; 1995 Apr; 154(8):4091-8. PubMed ID: 7706747
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells.
Jiang XP; Yang DC; Elliott RL; Head JF
Anticancer Res; 2011 Sep; 31(9):2899-906. PubMed ID: 21868536
[TBL] [Abstract][Full Text] [Related]
5. IL-6 antisense-mediated growth inhibition of a choriocarcinoma cell line: an intracellular autocrine growth mechanism.
Kong B; Isozaki T; Sasaki S
Gynecol Oncol; 1996 Oct; 63(1):78-84. PubMed ID: 8898173
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin 6 (IL-6) receptor influences the expression of the protooncogene junB and the production of fibrinogen in the HepG2 human hepatoma cell line and primary rat hepatocytes.
Igaz P; Tóth S; Rose-John S; Madurka I; Fejér G; Szalai C; Falus A
Cytokine; 1998 Aug; 10(8):620-6. PubMed ID: 9722935
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.
Levy Y; Tsapis A; Brouet JC
J Clin Invest; 1991 Aug; 88(2):696-9. PubMed ID: 1864979
[TBL] [Abstract][Full Text] [Related]
8. Negative modulation of signal transduction via interleukin splice variation.
Denessiouk KA; Denesyuk AI; Johnson MS
Proteins; 2008 May; 71(2):751-70. PubMed ID: 17979192
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 trans-signalling in chronic inflammation and cancer.
Scheller J; Ohnesorge N; Rose-John S
Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
[TBL] [Abstract][Full Text] [Related]
10. [Effect of IL-6/sIL-6R on ex vivo expansion of human cord blood derived CD34+ cells].
Feng JF; Zhuang M; Zhu LJ; Sheng ZL; Zhu YQ; Li CP
Ai Zheng; 2004 Jun; 23(6):715-8. PubMed ID: 15191679
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
12. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture.
Matsumiya T; Imaizumi T; Fujimoto K; Cui X; Shibata T; Tamo W; Kumagai M; Tanji K; Yoshida H; Kimura H; Satoh K
Exp Cell Res; 2001 Sep; 269(1):35-41. PubMed ID: 11525637
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
15. A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis.
Yoshida S; Harada T; Iwabe T; Taniguchi F; Mitsunari M; Yamauchi N; Deura I; Horie S; Terakawa N
Hum Reprod; 2004 Aug; 19(8):1821-5. PubMed ID: 15166129
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of plasma interleukin-6 soluble receptor in patients with essential thrombocythemia.
Marta R; Goette N; Lev P; Heller P; Kornblihtt L; Vassallú P; Glembotsky A; Pirola C; Molinas F
Haematologica; 2004 Jun; 89(6):657-63. PubMed ID: 15194532
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma.
Moran DM; Mayes N; Koniaris LG; Cahill PA; McKillop IH
Liver Int; 2005 Apr; 25(2):445-57. PubMed ID: 15780071
[TBL] [Abstract][Full Text] [Related]
18. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells.
Finotto S; Eigenbrod T; Karwot R; Boross I; Doganci A; Ito H; Nishimoto N; Yoshizaki K; Kishimoto T; Rose-John S; Galle PR; Neurath MF
Int Immunol; 2007 Jun; 19(6):685-93. PubMed ID: 17496315
[TBL] [Abstract][Full Text] [Related]
19. The soluble IL-6 receptors: serum levels and biological function.
Montero-Julian FA
Cell Mol Biol (Noisy-le-grand); 2001 Jun; 47(4):583-97. PubMed ID: 11502067
[TBL] [Abstract][Full Text] [Related]
20. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier.
Linker RA; Lühder F; Kallen KJ; Lee DH; Engelhardt B; Rose-John S; Gold R
J Neuroimmunol; 2008 Dec; 205(1-2):64-72. PubMed ID: 18950871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
